Paul J Tacken
Overview
Explore the profile of Paul J Tacken including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1424
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cruz L, Tacken P, van der Schoot J, Rueda F, Torensma R, Figdor C
Molecules
. 2019 May;
24(9).
PMID: 31083610
Optimal targeting of nanoparticles (NP) to dendritic cells (DCs) receptors to deliver cancer-specific antigens is key to the efficient induction of anti-tumour immune responses. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles containing...
2.
Cruz L, Tacken P, Eich C, Rueda F, Torensma R, Figdor C
Nanomedicine (Lond)
. 2017 Feb;
12(5):491-510.
PMID: 28181470
Aim: Dendritic cells rapidly capture nanoparticles and induce a potent cellular immune response. It is yet unknown whether the immunological response induced by slow release of encapsulated versus soluble antigen...
3.
Cruz L, Tacken P, Zeelenberg I, Srinivas M, Bonetto F, Weigelin B, et al.
Mol Pharm
. 2014 Oct;
11(12):4299-313.
PMID: 25290882
Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs), involved in the induction of immunity and currently exploited for antitumor immunotherapies. An optimized noninvasive imaging modality capable of determining...
4.
Kreutz M, Tacken P, Figdor C
Blood
. 2013 Feb;
121(15):2836-44.
PMID: 23390195
Vaccination is among the most efficient forms of immunotherapy. Although sometimes inducing lifelong protective B-cell responses, T-cell-mediated immunity remains challenging. Targeting antigen to dendritic cells (DCs) is an extensively explored...
5.
Tacken P, Ter Huurne M, Torensma R, Figdor C
Eur J Immunol
. 2012 Jun;
42(8):1989-98.
PMID: 22653683
DCs are regarded as key APCs that initiate humoral and cellular immune responses. Consequently, targeted delivery of Ag toward DC-specific receptors enhances vaccine efficacy. DC-SIGN is a C-type lectin receptor...
6.
Cruz L, Tacken P, Rueda F, Domingo J, Albericio F, Figdor C
Methods Enzymol
. 2012 May;
509:143-63.
PMID: 22568905
Dendritic cells (DCs) are key players in the initiation of adaptive immune responses and are currently exploited in immunotherapy for treatment of cancer and infectious diseases. Development of targeted nanodelivery...
7.
Aarntzen E, de Vries I, Goertz J, Beldhuis-Valkis M, Brouwers H, van de Rakt M, et al.
Cancer Immunol Immunother
. 2012 Apr;
61(11):2003-11.
PMID: 22527252
Purpose: Keyhole limpet hemocyanin (KLH) attracts biomedical interest because of its remarkable immunostimulatory properties. Currently, KLH is used as vaccine adjuvant, carrier protein for haptens and as local treatment for...
8.
Cruz L, Tacken P, Pots J, Torensma R, Buschow S, Figdor C
Biomaterials
. 2012 Mar;
33(16):4229-39.
PMID: 22410170
Vaccine efficacy is improved upon specific delivery to professional antigen (Ag) presenting cells, such as dendritic cells (DCs). Antigenicity and adjuvanticity of vaccine components can be enhanced by encapsulation within...
9.
Schreibelt G, Klinkenberg L, Cruz L, Tacken P, Tel J, Kreutz M, et al.
Blood
. 2012 Jan;
119(10):2284-92.
PMID: 22234694
CLEC9A is a recently discovered C-type lectin receptor involved in sensing necrotic cells. In humans, this receptor is selectively expressed by BDCA3(+) myeloid dendritic cells (mDCs), which have been proposed...
10.
Tacken P, Zeelenberg I, Cruz L, van Hout-Kuijer M, van de Glind G, Fokkink R, et al.
Blood
. 2011 Oct;
118(26):6836-44.
PMID: 21967977
Effective vaccines consist of 2 components: immunodominant antigens and effective adjuvants. Whereas it has been demonstrated that targeted delivery of antigens to dendritic cells (DCs) improves vaccine efficacy, we report...